Sugi Predict

Sugi Predict / Compounds / SCHEMBL2925857

SCHEMBL2925857

SCHEMBL2925857

C[C@@H]1CN(S(=O)(=O)c2c(C(N)=O)[nH]c3ccc(Cl)cc23)C[C@H](C)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP2 P11137 12/20 0.46
▸ ACLY P53396 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ TUBB4A P04350 1/20 0.40
▸ TUBB P07437 1/20 0.40
▸ TUBA3C P0DPH7 1/20 0.40
▸ TUBA1B P68363 1/20 0.40
▸ TUBA4A P68366 1/20 0.40
▸ TUBB4B P68371 1/20 0.40
▸ TUBB3 Q13509 1/20 0.40
▸ TUBB2A Q13885 1/20 0.40
▸ TUBB8 Q3ZCM7 1/20 0.40
▸ TUBA3E Q6PEY2 1/20 0.40
▸ TUBA1A Q71U36 1/20 0.40
▸ TUBA1C Q9BQE3 1/20 0.40
▸ TUBB6 Q9BUF5 1/20 0.40
▸ TUBB2B Q9BVA1 1/20 0.40
▸ TUBB1 Q9H4B7 1/20 0.40
▸ TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2923466 1.00 MAP2 (0.46) MAP2ACLYRXFP1SMN1; SMN2TUBB4A
SCHEMBL2923467 1.00 MAP2 (0.46) MAP2ACLYRXFP1SMN1; SMN2TUBB4A
SCHEMBL2925201 0.87 MAP2 (0.49) MAP2
SCHEMBL2927238 0.82 MAP2 (0.54) MAP2TSHRKMT2A
SCHEMBL2928734 0.82 MAP2 (0.51) MAP2TSHR
SCHEMBL3609940 0.82 MAP2 (0.51) MAP2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2927126 0.81 MAP2 (0.59) MAP2KMT2A
SCHEMBL2924539 0.81 MAP2 (0.53) MAP2TSHR
SCHEMBL3617971 0.81 MAP2 (0.46) MAP2TSHR
SCHEMBL3611987 0.81 MAP2 (0.47) MAP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534695-B1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME (US) 2010-09-29 — — EP claimed
US-7560546-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2009-07-14 — — US claimed
US-20050261496-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2005-11-24 — — US claimed
US-20040102360-A1 Combination therapy BARNETT STANLEY F (US) 2004-05-27 — — US claimed
EP-1534695-B1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME (US) 2010-09-29 — — EP disclosed
US-20090186871-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2009-07-23 — — US disclosed
US-20090186871-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2009-07-23 — — US disclosed
US-7560546-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2009-07-14 — — US disclosed
US-7560546-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2009-07-14 — — US disclosed
US-20050261496-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2005-11-24 — — US disclosed
US-20040102360-A1 Combination therapy BARNETT STANLEY F (US) 2004-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261496-A1 Tyrosine kinase inhibitors ABL1, JAK2, ERBB2 MAP2 732/4885ACLY 3558/4885RXFP1 706/4885
US-20040102360-A1 Combination therapy MTOR, AKT2, PLK1 MAP2 822/4885ACLY 862/4885RXFP1 4667/4885
US-20090186871-A1 Tyrosine kinase inhibitors ABL1, JAK2, ERBB2 MAP2 732/4885ACLY 3558/4885RXFP1 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.